ANTIPLATELET THERAPY IN THE PREVENTION OF CEREBROVASCULAR ACCIDENTS
https://doi.org/10.24884/1607-4181-2017-24-1-15-21
Abstract
Currently the problem of preventing cerebrovascular disorders, in which antiplatelet therapy takes one of the leading places, remains relevant. The efficiency of the therapy depends on a large number of modifiable and non-modifiable factors. There are many methods to assess the severity of the response to antiplatelet therapy, but there is no common approach to the assessment of the results and their prognostic significance. Further studies of this issue are essential with the aim of individualization of antiplatelet therapy thereby increasing its efficiency and safety.
About the Authors
O. V. Rodionova
Federal State Budgetary Educational Institution of Higher Education «Academician I. P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of the Russion Federation
Russian Federation
Russian Federation
Olga V. Rodionova - Neurologist of the neurological department №1 of the neurology clinic of the Scientific Research Institute of Neurology.
6/8 L’va Tolstogo street, Saint-Petersburg, 197022. E-mail: olgarodionovaspb@gmail.com
V. A. Sorokoumov
Federal State Budgetary Educational Institution of Higher Education «Academician I. P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of the Russion Federation
Russian Federation
Professor of the Department of Neurology
Russian Federation
Professor of the Department of Neurology
T. V. Vavilova
St. Petersburg State Budget-funded Healthcare Institution City Consultative and Diagnostic Center № 1
Russian Federation
MD, Professor, Head of the Department of Clinical Laboratory Diagnostics and Genetics, the chief freelance specialist in clinical laboratory diagnostics of the North-West Federal District; Hematologist of St. Petersburg SMU "Consultative and Diagnostic Center No. 1"
Russian Federation
MD, Professor, Head of the Department of Clinical Laboratory Diagnostics and Genetics, the chief freelance specialist in clinical laboratory diagnostics of the North-West Federal District; Hematologist of St. Petersburg SMU "Consultative and Diagnostic Center No. 1"
Y. D. Bogatenkova
St. Petersburg State Budget-funded Healthcare Institution City Consultative and Diagnostic Center № 1
Russian Federation
Candidate of medical sciences, head of neurological department
Russian Federation
Candidate of medical sciences, head of neurological department
M. M. Mnuskina
St. Petersburg State Budget-funded Healthcare Institution City Consultative and Diagnostic Center №1
Russian Federation
Head of clinical diagnostic laboratory
Russian Federation
Head of clinical diagnostic laboratory
I. G. Krupotkina
St. Petersburg State Budget-funded Healthcare Institution City Consultative and Diagnostic Center №1
Russian Federation
Doctor of clinical diagnostic laboratory
Russian Federation
Doctor of clinical diagnostic laboratory
L. A. Isaeva
St. Petersburg State Budget-funded Healthcare Institution City Consultative and Diagnostic Center №1
Russian Federation
Doctor of clinical diagnostic laboratory
Russian Federation
Doctor of clinical diagnostic laboratory
References
1. Gusev E.I., Skvortsova V.I., Stakhovskaya L.V. The problem of stroke in Russia: time active joint actions. Zhurnal nevrologii i psikhiatrii imeni S. S. Korsakova. 2007, no8, pp. 4–10. (In Russian).
2. Stakhovskaya L.V., Kotova S.V. Stroke: a guide for physicians. Moscow:MIA; 2014:15-23, 50-52, 87-94.(In Russ.)
3. Stakhovskaya L.V., Klochikhina O.A., Bogatyreva M.D., Kovalenko V.V.Epidemiology of stroke in Russia as a result of territorial and population register (2009-2010 g). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;(5):4-10. (In Russ.)
4. Adams H.P., Bendixen B.H., Kappelle L.J., et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993;24:35–41.
5. Babarro E.G., Rego A.R., Gonzalez-Juanatey J.R. Cardioembolic stroke: call for a multidisciplinary approach. Cerebrovasc Dis. 2009;27(1):82-7. DOI: 10.1159/000200444.
6. James F. Meschia, Cheryl Bushnell, Bernadette Boden-Albala, et al. Guidelines for the Primary Prevention of Stroke. Stroke. 2014;45(12): 3754–3832. DOI:10.1161/STR.0000000000000046.
7. Paulus Kirchhof, Stefano Benussi, DipakKotecha et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;1-90. DOI:10.1093/eurheartj/ehw210.
8. Walter N. Kernan, Bruce Ovbiagele, Henry R. Black, et al. Guidelines for the Prevention of Stroke in Patients With StrokeandTransientIschemicAttack.Stroke.2014;45:2160-2236.
9. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;(324):71-86.
10. Martsevich S.YU., Kutishenko N.P., Ginzburg M.L., Malysheva A.M., Polyanskaya YU.N. Antiplatelet therapy in patients with high risk of thrombotic complications: the problem of efficiency, safety and commitment.Klinitsist. 2011; (2): 72-79.(In Russ.)
11. Shuying Chen, QingyuShen, Yamei Tang, et al. Efficacy andSafetyofAddingClopidogreltoAspirinonStrokePrevention among High Vascular Risk Patients: A Meta-Analysis of Randomized Controlled Trials. Plos one. 2014;9(8):1-10. DOI:10.1371/journal.pone.0104402
12. DovgalevskiyP.YA., Furman N.V., Puchin’yan N.F. The clinical significance of resistance to aspirin in patients with cardiovascular disease patients.Rational Pharmacotherapy in Cardiology. 2006;(3):46-50.(In Russ.)
13. DinaldoCavalcanti de Oliveira, Rogerio Ferreira Silva, Diego Jantsk Silva, ValterCorreia de Lima. Aspirin Resistance: Fact or Fiction? Arq Bras Cardiol. 2010;95(3):91-94.
14. Ferguson A, Dokainish H, Lakkis N. Aspirin and Clopidogrel Response Variability Review of the Published Literature. Texas Heart Institute Journal. 2008;3:313-320.
15. Itsik Ben-Dor, Neal S Kleiman, Eli Lev. Assessment, Mechanisms, and Clinical Implication of Variability in Platelet Response to Aspirin and Clopidogrel Therapy. The American Journal of Cardiology. 2009;104(2):227-233. DOI:10.1016/j.amjcard.2009.03.022
16. Thomas J Oxley, Richard J Dowling, Peter J Mitchell, Stephen Davis, Bernard Yan. Antiplatelet resistance and thromboembolic complications in neurointerventional procedures. Frontiers in neurology. 2011;2:1-9. DOI: 10.3389/fneur.2011.00083.
17. Dominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, Fernando Alfonso, Carlos Macaya, Theodore A Bass, Marco A Costa. Variability in Individual Responsiveness to Clopidogrel. Clinical Implications, Management, and Future Perspectives. Journal of the American College of Cardiology. 2007;14:1505-1516.
18. Holmes DR Jr, Dehmer GJ, KaulS,et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA «boxed warning»: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am CollCardiol. 2010;56(4):321–341.
19. Shinichiro Uchiyama, Megumi Takeuchi, MikioOsawa, Itsuro Kobayashi, Shoichi Maruyama, Masahiko Aosaki, KoshichiroHirosawa. Platelet Function Tests in Thrombotic Cerebrovascular Disorders. Stroke. 1983;4:511-517.
20. Gabbasov Z.A. New highly sensitive method for the analysis of platelet aggregation. laboratornoyedelo. 1989; 10: 15–18.(In Russ.)
21. NalyakaSambu, Nick Curzen. Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. British Journal of Clinical Pharmacology. 2011;72:683-696. DOI:10.1111/j.1365-2125.2011.03955.x
22. Jean-Philippe Collet, Thomas Cuisset, GregoireRange et al. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. The new England journal of medicine. 2012; 367:2100-2109.
23. Matthew J Price, Peter B Berger, Paul S Teirstein et al. Standardvs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. The GRAVITAS Randomized Trial. JAMA. 2011;305(11):1097-1105. DOI: 10.1001/jama.2011.290.
24. Mirzayev K.B., Andreyev D.A., Sychev D.A. Evaluation of platelet aggregation in clinical practice. Rational Pharmacotherapy in Cardiology. 2015;11(1):85-91.(In Russ.)
25. Stone GW, Witzenbichler B, Weisz G et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382(9892): 614-623.
26. Janine Dretzke, Richard D Riley, Marie Lordkipanidze et al. The prognostic utility of tests of platelet function for the detection of ‘aspirin resistance’ in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. Health Technology Assessment. 2015;19. DOI 10.3310/hta19370
27. Conclusion of Interdisciplinary Expert Council of Russian Association of Angiologists and Vascular Surgeons, Russian Scientific Society of Endovascular Surgeons and Interventional Radiologists, National Stroke Association, National Scientific Inflammation Society. The significance of platelet functional activity testing in the prevention of cardiovascular complications in patients receiving antiplatelet therapy. Rational Pharmacotherapy in Cardiology. 2014;10(6): 679-687. (In Russ.)
28. Russian Ministry of Health Order of 29.12.2012 g №1692n approving the specialized medical care standards in intracerebral hemorrhage (conservative treatment). Available at: https://www.rosminzdrav.ru/documents/8969-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-29-dekabrya-2012-g-1692n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-vnutrimozgovom-krovoizliyanii-konservativnoe-lechenie. (In Russ.)
29. Russian Ministry of Health Order of 29.12.2012 №1740n approving the specialized medical care standard in cerebral infarction. Available at: https://www.rosminzdrav.ru/documents/8970-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-29-dekabrya-2012-g-1740n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-infarkte-mozga. (In Russ.)
30. Russian Ministry of Health Order of 29.12.2012 №1749n approving the specialized medical care standard in subarachnoid hemorrhage (conservative treatment). Available at: http://base.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=145061&fld=134&dst=1000000001,0&rnd=0.02678298372872079. (In Russ.)
31. Russian Ministry of Health Order of 29.12.2012 №1693n approving the specialized medical care standard for transient ischemic attack. Available at: https://www.rosminzdrav.ru/documents/8945-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-29-dekabrya-2012-g-1693n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-tranzitornoy-ishemicheskoy-atake. (In Russ.)
Review
For citations:
Rodionova O.V., Sorokoumov V.A., Vavilova T.V., Bogatenkova Y.D., Mnuskina M.M., Krupotkina I.G., Isaeva L.A. ANTIPLATELET THERAPY IN THE PREVENTION OF CEREBROVASCULAR ACCIDENTS. The Scientific Notes of the Pavlov University. 2017;24(1):15-21. (In Russ.) https://doi.org/10.24884/1607-4181-2017-24-1-15-21
Views:
1033
Email this article 